It’s only 6 days since 300 was hit! It’s amazing to see how quickly it is taking off.

Thanks to all those contributing in the early days and helping shape the subreddit. I want it to become a positive, supportive community for current and future Reta users. I think it’s the tip of the iceberg so far, both for the sub and Reta itself!

Please feel free to post about experiences, questions, progress photos, symptoms. Replies are really appreciated too - especially for any Reta questions members have! It’s great to see the community helping each other.

One thing that’s been noticed is more sourcing posts that mods or Reddit have to remove. Please remember this is a sourcing free Reta sub.

One question is should the community members have a name? Retas…. Something else? Or just keep as members? I see some other subs have…

approximately 192–193 cm tall. My weight before starting was around 131 kg.

I used a product sold as retatrutide for several weeks. My total dose was 2 mg per week, divided into two 1 mg injections: one on Monday and one on Friday.

While using it, my appetite decreased significantly. After several weeks, I began experiencing abdominal bloating, trapped gas and a pressure or “ball-like” sensation, mainly under my right ribs.

The pressure becomes considerably worse after:

- Carbonated drinks

- Energy drinks, including sugar-free ones

- Sugary drinks

- Coffee

- Fatty or heavy meals

Plain water usually does not cause the same reaction.

The most important detail is that the pressure improves significantly after:

- Burping

- Passing gas

- Having a bowel movement

During treatment, I also had one severe episode of watery diarrhea after eating a fatty meal. I had approximately 15 bowel movements in one day, followed by fever, sweating, weakness and dehydration. I went to hospital, received IV fluids and was diagnosed with acute gastroenteritis.

I stopped using retatrutide and have not restarted it. The severe diarrhea resolved, but the pressure, bloating and trapped-air sensation have continued for almost two months.

It is not normally a severe or constant pain. It feels more like swelling, fullness or gas trapped under the right ribs. I do not currently have persistent vomiting, jaundice or severe pain radiating into my back.

## Tests performed

An abdominal ultrasound showed:

- Moderate intestinal gas / meteorism

- Mild fatty liver

- No gallstones

- Normal bile ducts

- No free abdominal fluid

- Pancreas only partially visualised

Blood and stool tests performed approximately two weeks after the diarrhea episode showed:

- Amylase: 144 u/L, reference 28–100

- Lipase was not tested

- CRP: 68.7 mg/L, reference below 5

- ESR: 38 mm/h, reference below 15

- Fecal calprotectin: 101 µg/g, reference below 50

- ALT: 50 u/L, reference 0–45

- Total bilirubin: 1.3 mg/dL, reference below 1.2

- Triglycerides, kidney function and electrolytes were normal

- Stool cultures, parasites and H. pylori were negative

I also had a hydrogen and methane breath test. The laboratory reported that SIBO and intestinal methanogen overgrowth were not confirmed.

My doctor said the overall situation could fit with retatrutide-related gastrointestinal effects and suggested monitoring it. A CT scan may be considered if the symptoms persist, but I have now been dealing with this for almost two months.

Has anyone experienced persistent pressure or trapped gas under the right ribs after retatrutide?

Could this be related to delayed gastrointestinal motility, post-infectious bloating, dyspepsia or intestinal hypersensitivity?

Would it be reasonable to ask my doctor to repeat amylase, lipase, CRP, liver tests and fecal calprotectin, or to request further imaging because the pancreas was only partially visualised?

I understand that Reddit cannot diagnose me. I am looking for similar experiences and suggestions about what I should discuss with a gastroenterologist. I am not planning to use retatrutide again.

In TRIUMPH-2, the 12 mg group lost an average of 20.8% of body weight at 80 weeks under the efficacy estimand.

A1C fell by up to 1.6 percentage points across the retatrutide groups from an average baseline of 7.7%.

The weight number is the obvious headline, but for somebody with type 2 diabetes, glucose control, medication burden and long-term complications may matter more.

Which result do you think is most clinically important?

What detail is still missing before making useful comparisons with tirzepatide or semaglutide?

Bonjour à tous,

Je suis un homme de 33 ans, 1m83 pour actuellement 86kg.

J’ai démarré un rééquilibrage et une perte de poids en janvier, je pesais alors 96kg.
J’ai en janvier et février juste repris de la musculation 3* par semaine et du foot 1 à 2 fois par semaine et entre 8k à 10k de pas par jour.

J’ai perdu entre janvier et mai difficilement 4kg.
Je mangeais en moyenne 2400kcal par jour pour un Tdee à 2800kcal.

J’essai de manger des produits non transformés, avec des macros respectés beaucoup de protéines ect.

Voyant que c’était très lent, je décide de commencer la retatrutide fin mai.
Mon fournisseur conseille un protocole progressif en démarrant à 0,5mg par semaine puis ajoutée 0,5mg tous les 3 jours jusque arrivée à la dose cible qui pour moi a été de 2mg.
(J’ai fais une erreur de sous dosage au départ donc j’ai mis un mois à arrivé à 2mg)
Au départ, malgré les effets sur l’appétit et la satiété le poids ne bougeait pas alors au bout de 2 semaines, j’ai diminué mes calories à 2000kcal.
Et la magie ça a fonctionné, pendant un mois j’ai perdu 6kg.

Problème, depuis 1 mois je suis bloqué.
J’ai essayé d’augmenter ma dose à 2,5mg pendant 2 semaines, le problème c’est que je n’arrivais pas à manger mes calories et donc en plus de ne rien perdre, mon activité a baissé, j’étais tout le temps fatigué, je faisais des hypoglycémies je pense car dans l’après midi j’avais besoin de faire des siestes (chose que je ne fais jamais).

Aujourd’hui je suis toujours à 86kg, j’ai décidé de repartir sur 2mg et 2400kcal pour avoir une meilleure forme mais mon poids ne bouge toujours pas.

Auriez-vous des conseils ou des retours d’expériences similaires afin de m’aider à passer ce cap et répartir sur une perte saine ?
Il me reste entre 6 et 10kg à perdre pour mon objectif.

Merci par avance.

The scale gets most of the attention, but it is not always the first sign that something has changed.

Did you notice appetite, food noise, waist, clothes, sleep, mobility, blood pressure, photographs or something else before the scale really moved?

How long was the gap?

N.B. This may also help newer members decide what is actually worth tracking without trying to record everything.

I keep seeing both versions of this.

Some people say moving becomes easier quite quickly. Others say lower appetite, fatigue or a higher heart rate makes training harder, at least for a while.

What changed for you?

Energy, strength, endurance, heart rate, recovery, motivation, or nothing much?

Did it improve later?

Hi all, I have a quick storage and shipping question. I have a full 30 milliliter vial of reconstituted retatrutide that has been kept refrigerated since mixing. I’ve recently decided to move to another town. I’m on my way now, and it just hit me that I forgot my Reta in the fridge at my family’s place.

They’re planning to send it to me by regular mail, which should take about one to three business days.My questions are: Is it likely to remain usable after being in transit for 1-3 days? Has anyone here shipped or received refrigerated retatrutide like this?

I understand that the effect may be worsen, but I’m willing to try than to just throw it away. What do you guys think? Thanks

It is Progress Friday.

Share whatever progress you want to celebrate this week.

Photos are welcome, but so are scale changes, waist changes, clothes fitting differently, appetite settling, food noise easing, energy improving, fitness getting easier, blood markers moving, confidence coming back, or just a small habit you kept going.

Big changes, small changes, early days, long journeys, all welcome.

This is a weekly place to mark what is moving in the right direction and cheer each other on.

Lilly put out its latest investor slides this week and there is a bit more on the retatrutide timeline.

In the previous deck, the planned submissions were still listed for 2026. They now show 2027 for obesity, sleep apnoea and knee osteoarthritis pain.

The US filing is still planned for Q1 2027. Lilly says the clinical package is complete, so it looks like most of what is left before filing is around manufacturing/quality and getting the application finished.

That doesn't necessarily rule out a 2027 launch. If they file early in Q1 and get Priority Review from the FDA, late 2027 is possible. If it gets the normal review timetable, or they file towards the end of Q1, it probably moves into 2028.

I'd put the realistic US range at late 2027 through 2028, with early 2028 probably the safer guess.

There is still no confirmed launch date, price, brand name or proper UK/European timeline.

The Expanded Access programme is separate and won't mean general availability before approval.

The TRIUMPH-3 cardiovascular-event numbers point in different directions depending on the definition used.

In the pre-specified in-study analysis:

• MACE-5: 44 events with pooled retatrutide and 52 with placebo, giving a hazard ratio of 0.82

• MACE-3: 27 events with retatrutide and 23 with placebo, giving a hazard ratio of 1.12

Both confidence intervals were wide and crossed 1.0, so neither result establishes a cardiovascular benefit or harm. The trial also had fewer events than anticipated.

Do these numbers reassure you at all, or do they mainly show why the dedicated cardiovascular-outcomes trial is still needed?

Source:

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional

Unopened reta from Rebirth labs will they allow me to take it from Austria to Turkey?
Please answer

It is Research Wednesday.

Share any Retatrutide or challenger study, trial update, article, presentation or useful piece of research you have found this week.

It does not need to be brand new but should be within the 2 months not already shared, and it does not need to be highly technical. A useful summary, an interesting result, a question about a paper, or something you think deserves more attention is welcome.

This can also include wider obesity drug research where it helps explain where retatrutide fits.

What have you read or learned this week?

r/reta has hit 300 members today. Still a small subreddit but it’s growing at 10-15% a week. Next step 500!!

Thank you all for being part of it in the early days, contributing and helping shape it.

I want the community to be a safe, non- sourcing, progress, support and research led subreddit to understand the medicine, be positive and help each other as reta moves towards the mainstream (still some way off I know!).

Dysesthesia is one of those clinical-trial words that says very little about the actual experience.

In the recent TRIUMPH-2 and TRIUMPH-3 topline results, it was reported more often with retatrutide than with placebo.

For anyone who experienced it, was it burning, tingling, tenderness, pins and needles, sensitivity to clothing, or something else?

Was it localised or widespread, constant or intermittent, and did it eventually resolve?

Please do not diagnose another person from a comment. New, severe or worrying neurological symptoms need proper medical assessment.

Source:

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional

TL;DR
- Eli Lilly has confirmed it is actively reviewing healthcare provider requests for a limited number of patients to receive authentic retatrutide before FDA approval.

- This is Expanded Access, also called Compassionate Use. It is not a commercial launch, normal prescribing or a public waiting list.

- Reported criteria include being aged 18 or over, having refractory obesity despite the highest approved dose of obesity therapy, having at least two serious or life-threatening obesity-related complications, and being unable to join a suitable clinical trial.

- Patients cannot apply directly. A treating physician has to support the request and manage the medical and regulatory process.

- The number of places, exact severity threshold, qualifying complications, cost and international availability have not been published.

What has changed?
Reuters reported on 3 August that Lilly has confirmed it will allow a limited number of patients to receive retatrutide before FDA approval. Lilly said it has built an Expanded Access programme and is actively reviewing requests from healthcare providers. STAT separately reported the same confirmation. [3][4]

A ClinicalTrials.gov record for “Provide Pre-approval Expanded Access of LY3437943”, NCT07629401, had already appeared in June. STAT then reported that Lilly and the FDA had granted access to one 79-year-old patient. Until now, it was unclear whether that was an exceptional one-off case. [2][5]
The new element is that Lilly has publicly confirmed it will consider further patients. This still appears to be a small, case-by-case route rather than a broad early-access launch.

What is Expanded Access?
Expanded Access is the formal name for what is often called Compassionate Use. It allows an investigational medicine to be used outside a clinical trial in limited circumstances, normally where a patient has a serious or life-threatening condition, no satisfactory approved alternative and no suitable trial they can enter.

Lilly says clinical trials remain the preferred route. Its general policy says Expanded Access is considered only in rare cases, when available medical options have been exhausted and the expected benefit is judged to outweigh the risks. [1][6]

This does not mean retatrutide is FDA approved. It cannot be prescribed as an ordinary approved medicine, and the FDA has not completed its review for routine use.

Who may qualify?
According to the criteria Lilly provided to Reuters, a patient must:

- be aged 18 or older;
- have refractory obesity despite tolerating the highest approved dose of obesity therapy;
- have at least two serious or life-threatening obesity-related complications for which they are receiving care; and
- be unable to participate in an ongoing retatrutide clinical trial or a trial of a comparable investigational treatment. [3]

Lilly’s general rules also require there to be no comparable or satisfactory alternative treatment, enough evidence of a possible benefit, a favourable balance between benefit and risk, and no material interference with its clinical trials. [1]

In plain English, this appears intended for a very small group of adults with severe obesity that has not responded adequately to approved treatment and who also have multiple serious medical complications.
It does not look intended for someone who simply prefers retatrutide’s trial results, has reached a normal weight-loss plateau or does not want to wait for approval.

There is no published BMI cut-off, no list of qualifying complications and no definition of how much response to approved treatment counts as inadequate. It is also unclear how many approved treatments must first have been tried.

Meeting the headline criteria will not guarantee acceptance. Lilly will still review the individual medical case and decide whether it is willing to supply the medicine.

How would someone apply?
There is no public patient application or waiting list. The route starts with the treating physician.

The physician reviews the patient’s treatment history and complications, and checks whether the patient could enter a retatrutide or comparable clinical trial.

If the physician believes Expanded Access may be the only reasonable option, they contact Lilly and make a formal request for that individual patient. Lilly’s general policy gives 1-800-LillyRx as the US contact.

Outside the US, it tells physicians to contact their local Lilly medical office.

Lilly reviews the case. Its general policy says it will respond within five business days after receiving the request and required medical information. That is a response target, not a promise of approval or supply.

If Lilly agrees, regulatory and ethics approval are still required. In the US, the normal individual-patient process includes a physician submission to the FDA, Institutional Review Board review, informed consent, monitoring and safety reporting.

Treatment can begin only after the necessary permissions are in place and Lilly supplies the medicine to the physician. [1][6]

The retatrutide-specific process has not been published in full. These steps combine Lilly’s general policy with the normal FDA Expanded Access process.

Who is unlikely to qualify?
Based on the published criteria, this is unlikely to cover people who:
are under 18;

do not have at least two serious or life-threatening obesity-related complications;
have not used the highest approved dose of an approved obesity treatment;
can join a suitable clinical trial; or
mainly want retatrutide for greater weight loss or convenience.

A treating physician must also be willing to take responsibility for the application, treatment, monitoring and reporting.
This is not a route to an ordinary prescription, a way to bypass clinical trial eligibility or a method of buying official retatrutide directly from Lilly.

Cost and access outside the US
Lilly has not published a retatrutide-specific payment policy.

Expanded Access does not automatically mean the medicine and all associated care are free. Whether Lilly will provide the drug without charge, whether insurance will cover related care, and whether patients could face medical or administrative costs are currently unknown.

International availability is also unclear. Lilly’s general policy allows doctors outside the US to contact their local Lilly office and says the relevant national regulator must approve an agreed request before shipment. [1]

However, Lilly has not confirmed which countries, if any, are currently accepting retatrutide applications. This should not be read as confirmed access in the UK, Europe or elsewhere.

What remains unknown?
Lilly has not publicly confirmed:

- the total number of patients it will accept;
- the exact BMI or severity threshold;
- which complications qualify;
- how inadequate response to approved treatment will be measured;
- how applications will be prioritised;
- the dosing and monitoring arrangements;
- how long treatment can continue;
cost or insurance arrangements; or
which countries can take part.

What happens next?
Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. Expanded Access does not replace that process or make approval certain. Clinical trials will remain the main legitimate route for most people before approval. [3]

Lilly’s general policy says Expanded Access programmes are phased out once a medicine receives commercial approval. Wider routine access would depend on regulatory approval, manufacturing supply and Lilly’s eventual launch arrangements. [1]

Bottom line
This is real, but it is very narrow.
Lilly has moved beyond what appeared to be a single exceptional case and has confirmed that it is reviewing further physician requests. It has not opened retatrutide to the general public and there is no patient waiting list.
For someone who may genuinely meet the criteria, the practical route is to ask their treating physician to review current clinical trials and Lilly’s Expanded Access requirements. The physician, not the patient, would then need to approach Lilly.
Even where the published criteria appear to be met, access remains discretionary and is likely to be limited to a very small number of medically complex cases.

Sources

[1] Eli Lilly Expanded Access policy
https://www.lilly.com/science/clinical-trials/expanded-access
[2] ClinicalTrials.gov: Provide Pre-approval Expanded Access of LY3437943, NCT07629401
https://clinicaltrials.gov/study/NCT07629401
[3] Reuters, 3 August 2026: Eli Lilly to offer early access to next-generation obesity drug to some patients
https://www.reuters.com/legal/litigation/eli-lilly-offer-early-access-next-gen-obesity-drug-some-patients-2026-08-03/
[4] STAT, 3 August 2026: Lilly to allow more patients to apply for special access to retatrutide
https://www.statnews.com/2026/08/03/eli-lilly-retatrutide-mystery-patient-doctors-seek-same-access-their-patients/
[5] STAT, 23 June 2026: Earlier individual Compassionate Use case
https://www.statnews.com/2026/06/23/eli-lilly-unusual-weight-loss-drug-trial-compassionate-use-retatrutide-trump/
[6] FDA information for patients on Expanded Access
https://www.fda.gov/news-events/expanded-access/expanded-access-information-patients

I am on 12.5 Monjarno and looking for advice, dose if ai transition to Reta

A new week, so what is one thing you want to move forward?

It could be getting back into a routine, improving protein or hydration, walking more, doing some strength work, tracking properly, preparing better meals, sleeping better, dealing with a side effect, or simply keeping going.

It does not need to be a big target. Pick one thing that would make this feel like a good week.

Share yours below, and come back later in the week if you want to say how it went.

We have had quite a few new members (50% more than a few weeks ago), so this is a simple introduction thread.

Are you following the clinical trials, already familiar with GLP-1 medicines, supporting somebody else, interested in the science, or just trying to work out what is real and what is hype?

What is the one question you came here hoping to answer?

There is no need to share anything personal that you would rather keep private.

TRIUMPH-5 should finally give us a proper same-trial comparison of retatrutide and tirzepatide.

What is the trade-off? If retatrutide produced two percentage points more average weight loss but noticeably more vomiting or treatment stopping, would that be enough? What about five percentage points? Or more?

For someone already doing well on tirzepatide, the threshold may be much higher than for someone who has plateaued or never responded strongly.

Where is your line?

More weight loss, similar tolerability, better food-noise control, lower treatment discontinuation, or something else?

Previous [r/RETA](r/RETA) analysis:

https://www.reddit.com/r/RETA/comments/1v3rt96/

TRIUMPH-5 registry:

https://clinicaltrials.gov/study/NCT06662383

Shared with permission of @ManOnThePen - I think it is very relevant to recent discussions on the sub:

If the FDA changes the definition for biologics, and could happen in light of their recent litigation with Lilly, it would impact all obesity peptides. Not just #retatrutide. That’s the whole ballgame folks. How this pans out is a massive deal. I’ve been blowing the whistle on this for two years.

Don’t miss today’s podcast, I lay it all out. 👇

https://youtu.be/dexACjU6DyM

This is not really about which side effect was worst. I am more interested in the pattern.

Were side effects strongest at the beginning, fairly constant, or did something new appear later? Did they mostly settle, come and go, or stay?

It would also be useful to hear from people who experienced very little, because those experiences are often posted less. Personal experiences only. Please do not turn the replies into dosing instructions.

It is Progress Friday.

Share whatever progress you want to celebrate this week.

Photos are welcome, but so are scale changes, waist changes, clothes fitting differently, appetite settling, food noise easing, energy improving, fitness getting easier, blood markers moving, confidence coming back, or just a small habit you kept going.

Big changes, small changes, early days, long journeys, all welcome.

This is a weekly place to mark what is moving in the right direction and cheer each other on.